Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting ...

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.